Top 10 Healthcare Companies by Revenue in 2026
Last Updated: August 2026
Which are the world's largest healthcare companies by revenue in 2026? The answer is broader than a simple list of pharmaceutical companies. The global healthcare industry includes health insurers, pharmacy benefit managers, pharmaceutical distributors, healthcare services companies, medical-product distributors and diversified healthcare businesses.
This updated ranking uses the latest reported full-year revenue available as of August 2026. Because companies have different fiscal year-ends, the comparison uses each company's most recently completed fiscal year rather than forcing every company into the same calendar period.
Top 10 Healthcare Companies by Revenue: 2026 Ranking
Based on the latest reported annual revenue available as of August 2026, the leading companies are:
- UnitedHealth Group (NYSE: UNH) — approximately $447.6 billion
- McKesson (NYSE: MCK) — approximately $403.4 billion
- CVS Health (NYSE: CVS) — approximately $402.1 billion
- Cencora (NYSE: COR) — approximately $321.3 billion
- The Cigna Group (NYSE: CI) — approximately $274.9 billion
- Cardinal Health (NYSE: CAH) — approximately $254.2 billion
- Centene (NYSE: CNC) — approximately $174.6 billion in premium and service revenue
- Elevance Health (NYSE: ELV) — approximately $199.1 billion total revenue
- Humana (NYSE: HUM) — approximately $129.7 billion
- Johnson & Johnson (NYSE: JNJ) — approximately $94.2 billion
 |
| Source: CompaniesMarketCap.com |
Ranking note: The precise ordering of diversified healthcare companies can vary depending on whether researchers use total reported revenue, operating revenue, premiums and services, or a narrower definition of healthcare revenue. For consistency, this article primarily uses each company's reported consolidated revenue or the closest comparable top-line measure.
Related: Largest Healthcare Companies by Country 2026.
How We Rank the Largest Healthcare Companies
Revenue is one of the simplest ways to compare the economic scale of healthcare businesses, but it is not a perfect measure of business quality or investment attractiveness.
For this ranking, OneDayAdvisor uses:
- The latest completed fiscal year reported by the company.
- Company annual reports, regulatory filings and official earnings releases where available.
- Consolidated revenue or the company's principal reported top-line revenue measure.
- Publicly traded companies with substantial healthcare operations.
- Approximately comparable revenue figures rather than market capitalization.
Fiscal years differ. UnitedHealth and CVS report on a calendar-year basis, while McKesson's fiscal year ends March 31 and Cencora's fiscal year ends September 30. This means the ranking is best interpreted as a measure of recent annual business scale, not a perfectly synchronized 2026 calendar-year ranking.
Company-by-Company Analysis
1. UnitedHealth Group — $447.6 Billion
$447.6B revenue
NYSE: UNH Health Insurance Optum Healthcare ServicesUnitedHealth Group remains the world's largest healthcare company by revenue in this ranking. The company reported $447.6 billion in 2025 revenue, up approximately 12% from $400.3 billion in 2024.
UnitedHealth is unusual because its scale extends well beyond traditional health insurance. Its businesses include UnitedHealthcare and Optum, with activities spanning health benefits, pharmacy services, healthcare delivery, technology, analytics and related services.
UnitedHealthcare generated approximately $344.9 billion of 2025 revenue, while Optum generated approximately $270.6 billion. Because these businesses operate within the same corporate group, their revenues should not be added together when calculating consolidated company revenue.
2. McKesson — $403.4 Billion
$403.4B revenue
NYSE: MCK Pharmaceutical Distribution Oncology Healthcare ServicesMcKesson moved into second place after reporting $403.4 billion in fiscal 2026 revenue, representing approximately 12% year-over-year growth.
McKesson is one of the world's largest pharmaceutical and healthcare-product distribution companies. Its operations include pharmaceutical distribution, oncology and multispecialty services, prescription technology solutions and medical-surgical products.
The company's fiscal 2026 revenue growth was particularly notable in oncology and multispecialty operations, which generated approximately $48.4 billion in revenue and increased 31% year over year.
McKesson's enormous revenue base illustrates an important feature of healthcare economics: distributors can generate hundreds of billions of dollars in annual sales even though their business model is fundamentally different from that of drug manufacturers.
3. CVS Health — $402.1 Billion
$402.1B revenue
NYSE: CVS Health Insurance PBM PharmacyCVS Health reported record 2025 revenue of approximately $402.1 billion, an increase of 7.8% from the previous year.
CVS combines several major healthcare businesses, including Aetna, CVS Caremark and CVS Pharmacy. This integrated model gives the company exposure to health insurance, pharmacy benefit management, retail pharmacy and healthcare services.
The company's scale makes it one of the most important healthcare businesses in the United States, but its revenue should be interpreted alongside medical benefit costs, pharmacy costs, operating margins and cash flow.
CVS also illustrates why healthcare rankings based only on revenue can sometimes be misleading: a large portion of revenue can flow through a business as premiums, pharmaceutical costs or reimbursed healthcare spending.
4. Cencora — $321.3 Billion
$321.3B revenue
NYSE: COR Pharmaceutical Distribution Specialty PharmaceuticalsCencora, formerly known as AmerisourceBergen, reported approximately $321.3 billion in fiscal 2025 revenue, up 9.3% year over year.
The company provides pharmaceutical sourcing and distribution services and has significant exposure to specialty pharmaceuticals, healthcare providers and biopharmaceutical companies.
Cencora's position near the top of the global healthcare revenue rankings reinforces the importance of pharmaceutical distribution. The largest healthcare companies are not necessarily the companies that discover and manufacture the medicines themselves.
5. The Cigna Group — $274.9 Billion
$274.9B revenue
NYSE: CI Health Services Insurance Pharmacy ServicesThe Cigna Group reported approximately $274.9 billion in total revenue for 2025.
Cigna operates through a broad healthcare-services ecosystem. Its businesses include health benefits and pharmacy-related services, giving the company exposure to both healthcare financing and healthcare delivery infrastructure.
The company illustrates another major healthcare trend: the growing importance of services businesses that sit between patients, employers, insurers, pharmaceutical manufacturers and healthcare providers.
6. Cardinal Health — $254.2 Billion
$254.2B revenue
NYSE: CAH Medical Distribution PharmaceuticalsCardinal Health reported approximately $254.2 billion in fiscal 2026 revenue, up 14% from $222.6 billion in fiscal 2025.
Cardinal Health distributes pharmaceuticals and medical products and serves pharmacies, hospitals, health systems, ambulatory care providers and other healthcare organizations.
The company's growth highlights the continued importance of distribution infrastructure as healthcare systems become increasingly complex and pharmaceutical utilization expands.
7. Elevance Health — $199.1 Billion
$199.1B revenue
NYSE: ELV Health Insurance Healthcare ServicesElevance Health reported approximately $199.1 billion in total 2025 revenue.
The company provides health plans and a range of healthcare-related services, including clinical, behavioral, pharmacy and complex-care solutions.
Elevance is an important example of the scale achieved by large managed-care organizations. Its business is heavily influenced by medical costs, government healthcare programs, reimbursement trends and enrollment changes.
8. Centene — $174.6 Billion
$174.6B premium and service revenue
NYSE: CNC Medicaid Medicare MarketplaceCentene reported approximately $174.6 billion in 2025 premium and service revenue, up about 20% from 2024.
Centene is particularly important in government-sponsored healthcare, including Medicaid and Medicare-related businesses, as well as health insurance marketplace products.
The company also demonstrates why healthcare-company rankings should be read with an understanding of policy exposure. Changes in Medicaid enrollment, reimbursement, risk adjustment and government healthcare policy can materially affect revenue and profitability.
9. Humana — $129.7 Billion
$129.7B revenue
NYSE: HUM Medicare Advantage Healthcare ServicesHumana reported approximately $129.7 billion in 2025 total revenue.
Humana is strongly associated with Medicare Advantage and healthcare services for older adults. Its revenue growth reflects the scale of the aging population and the increasing importance of government-sponsored healthcare programs.
For investors, however, membership growth alone is not enough. Medical cost trends, reimbursement rates, benefit design and regulatory changes can have a major effect on profitability.
10. Johnson & Johnson — $94.2 Billion
$94.2B sales
NYSE: JNJ Pharmaceuticals MedTech OncologyJohnson & Johnson reported $94.2 billion in worldwide sales for 2025, up 6.0% from 2024.
Unlike several companies higher on this list, Johnson & Johnson derives its revenue primarily from innovative medicines and medical technology rather than health insurance or pharmaceutical distribution.
Its Innovative Medicine business generated approximately $60.4 billion in 2025 sales, while MedTech generated approximately $33.8 billion.
This makes Johnson & Johnson a useful benchmark for understanding the difference between healthcare revenue scale and pharmaceutical and medical-technology innovation.
What Is Driving Healthcare Industry Revenue in 2026?
The world's largest healthcare companies are benefiting from several long-term structural trends.
1. Aging populations
Population aging is increasing demand for medicines, chronic-disease management, surgery, diagnostics, insurance and long-term healthcare services.
2. Specialty pharmaceuticals
Oncology, immunology, rare diseases and other specialty therapies are becoming increasingly important parts of the pharmaceutical economy. Distribution companies such as McKesson and Cencora also benefit from increasing specialty-drug utilization.
3. GLP-1 medicines
GLP-1 and related metabolic medicines have become one of the most important pharmaceutical growth categories. Their impact extends beyond drug manufacturers to pharmacies, insurers, pharmacy benefit managers and healthcare providers.
4. Healthcare consolidation
Large healthcare companies increasingly combine insurance, pharmacy, technology, distribution, clinical services and data capabilities. This creates enormous revenue scale but can also make companies more complex to analyze.
5. Healthcare technology and AI
Artificial intelligence is increasingly being applied to drug discovery, medical imaging, clinical decision support, administrative automation, claims processing, healthcare analytics and patient engagement.
6. Oncology and specialty care
Cancer care remains one of the largest and fastest-evolving areas of healthcare spending. New targeted therapies, immunotherapies, cell therapies, antibody-drug conjugates and precision-medicine approaches are creating new markets for pharmaceutical manufacturers, distributors and healthcare providers.
What the Revenue Ranking Means for Investors
A company's revenue is useful for measuring scale, but revenue alone does not tell investors whether a stock is cheap or expensive.
Healthcare businesses have very different economic models. A pharmaceutical distributor may generate hundreds of billions of dollars in revenue while operating on relatively thin margins. A pharmaceutical company may generate much less revenue but retain significantly higher gross and operating margins.
Investors should therefore examine:
- Revenue growth — Is sales growth accelerating or slowing?
- Gross margin — How much revenue remains after direct costs?
- Operating margin — How efficiently does the company convert revenue into operating profit?
- Free cash flow — How much cash does the business actually generate?
- Debt — Is the balance sheet resilient?
- Return on invested capital — Is management creating value from the capital deployed?
- Valuation — How much are investors paying for earnings, cash flow and sales?
- Competitive advantage — Does the company have scale, intellectual property, network effects or other durable advantages?
- Regulatory exposure — How dependent is the company on government reimbursement and policy?
Healthcare Companies by Business Model
The top 10 can also be grouped according to their primary economic model.
- Health insurance and managed care: UnitedHealth, Cigna, Elevance, Centene and Humana.
- Pharmaceutical distribution: McKesson, Cencora and Cardinal Health.
- Integrated healthcare: CVS Health.
- Innovative medicines and medical technology: Johnson & Johnson.
This distinction is important because companies in different categories should not necessarily be compared using the same valuation metrics.
Revenue vs. Market Capitalization
One of the most common mistakes in healthcare-stock analysis is confusing revenue with market capitalization.
Revenue measures the amount of business flowing through a company. Market capitalization represents the market value of its outstanding equity.
Consequently, a company with $100 billion in revenue can be worth substantially more or less on the stock market than another company generating $100 billion in revenue.
The difference is driven by profitability, expected growth, capital intensity, balance-sheet risk, competitive advantages and investor expectations.
For this reason, OneDayAdvisor maintains separate rankings for healthcare companies by revenue, market capitalization and investment attractiveness.
Why Pharmaceutical Companies Do Not Dominate This List
A surprising feature of the ranking is that most of the largest healthcare companies are not traditional pharmaceutical manufacturers.
That is because pharmaceutical companies generally recognize revenue from products they manufacture and sell, while insurers, pharmacy benefit managers and distributors can process enormous amounts of healthcare spending.
For example, McKesson and Cencora can generate hundreds of billions of dollars in annual revenue because they distribute medicines at enormous scale. Their revenue economics are fundamentally different from those of a company such as Johnson & Johnson.
Therefore, a ranking of the largest healthcare companies should not be confused with a ranking of the largest pharmaceutical companies.
For pharmaceutical-specific rankings, see the related OneDayAdvisor coverage of the world's largest pharmaceutical companies.
Important Limitations
This ranking is designed as an educational and investment-research reference rather than a definitive real-time league table.
- Companies have different fiscal year-end dates.
- Revenue definitions differ between insurers, distributors, pharmaceutical companies and healthcare-service providers.
- Currency conversion can change the relative position of international companies.
- Corporate acquisitions, divestitures and accounting changes can materially affect year-to-year comparisons.
- Revenue does not measure profitability or shareholder returns.
- A high-growth company may have lower current revenue but substantially greater future potential.
- Private healthcare companies may be excluded because comparable financial information is not always publicly available.
Frequently Asked Questions
What is the largest healthcare company in the world by revenue?
UnitedHealth Group is the largest healthcare company in this ranking, with approximately $447.6 billion of revenue for 2025.
Is McKesson bigger than CVS Health by revenue?
Based on the latest completed fiscal years available in August 2026, yes. McKesson reported approximately $403.4 billion in fiscal 2026 revenue, compared with CVS Health's approximately $402.1 billion in 2025 revenue.
What is the largest pharmaceutical company by revenue?
The answer depends on how pharmaceutical revenue is defined and whether diversified healthcare companies are included. Pharmaceutical-company rankings should therefore be separated from broader healthcare-company rankings.
Is revenue a good way to rank healthcare stocks?
Revenue is useful for measuring company scale, but it is not sufficient for investment analysis. Investors should also examine earnings growth, margins, free cash flow, debt, valuation, competitive advantages and regulatory risk.
Why are pharmaceutical distributors so high on the list?
Distributors process enormous volumes of medicines and healthcare products. Their revenue can therefore be extremely large even though their profit margins are generally much lower than those of some innovative pharmaceutical companies.
Are these the best healthcare stocks to buy?
No. This is a revenue ranking, not a buy ranking. A company's size does not determine whether its shares are attractively valued.
Bottom Line
The 2026 healthcare revenue landscape is dominated by enormous, diversified organizations rather than traditional drug manufacturers alone.
UnitedHealth Group leads the ranking at approximately $447.6 billion in annual revenue, followed by McKesson at $403.4 billion and CVS Health at $402.1 billion. Cencora, Cigna, Cardinal Health, Elevance, Centene, Humana and Johnson & Johnson round out the leading group.
The ranking also reveals an important structural feature of modern healthcare: enormous economic value exists across the entire healthcare ecosystem—from insurance and pharmacy benefits to drug distribution, specialty care, innovative medicines, medical technology and healthcare data.
For investors, however, size is only the starting point. The more important question is how effectively each company converts its revenue into sustainable earnings and free cash flow, and whether the current stock price adequately reflects its future growth prospects.
Sources and Data Methodology
Primary financial data should be verified against the latest company annual reports, SEC filings and official earnings releases. Key figures used in this update include UnitedHealth Group's 2025 results, McKesson fiscal 2026 results, CVS Health 2025 results, Cencora fiscal 2025 results, Cigna's 2025 results, Cardinal Health fiscal 2026 results, Elevance Health 2025 results, Centene 2025 results, Humana 2025 results and Johnson & Johnson 2025 results.
Last reviewed: August 20, 2026. Revenue figures are rounded for readability. Fiscal-year periods differ by company. Where a company's reporting convention differs from standard consolidated revenue, the article identifies the relevant measure.
Disclaimer
The information presented in this article, "Top 10 Healthcare Companies by Revenue" is intended for general informational purposes only and should not be construed as professional financial, investment, or medical advice. The revenue figures, company rankings, and projections are based on publicly available data, company reports, and industry estimates as of 2025. All currency conversions, where applicable, are based on annual average exchange rates, and revenues outside the health sciences sector have been excluded for consistency (1).
While efforts have been made to ensure the accuracy and timeliness of the information, One Day Advisor and the article’s authors do not guarantee the completeness, reliability, or suitability of the content for any particular purpose. Readers are encouraged to verify details independently and consult qualified professionals before making any business, investment, or healthcare decisions based on the information provided.
The article may reference ongoing developments, regulatory actions, or market events that are subject to change. One Day Advisor is not responsible for any losses or damages arising from the use of this information.
Top 10 Pharmaceutical Companies by Revenue
Top 10 Drugs by Worldwide Sales
.png)
Comments